Mass General Brigham at CTAD 2026
Nov 16–19, 2026 Boston, MA ~1.7k attendees Website
Mass General Brigham takes part in 20 sessions at CTAD 2026 in Boston, its home city. Its program spans anti-amyloid therapy safety, blood biomarkers and imaging, with ARIA risk prediction a recurring thread. Its work includes low-field MRI for monitoring ARIA-E and plasma p-tau217 risk models in multi-cohort studies.
| Organization | CTAD 2026 Attendance |
|---|---|
Mass General Brigham Boston, Massachusetts | |
Boston health system that includes Massachusetts General and Brigham and Women's hospitals; runs large Alzheimer's research and trial programmes. | Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Talk Mon Nov 16 4:35pm Talk Tue Nov 17 10:20am Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Poster Wed Nov 18 7:15am–5:30pm Talk Wed Nov 18 4:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm Poster Thu Nov 19 7:15am–5:00pm |
Instantly find 20 buyers from Mass General Brigham
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction